Previous Article | Next Article ![]()
Molecular and Cellular Biology, August 2002, p. 5793-5800, Vol. 22, No. 16
0270-7306/02/$04.00+0 DOI: 10.1128/MCB.22.16.5793-5800.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Department of Molecular Biology, Princeton University, Princeton, New Jersey 08544,1 Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, Rhode Island 029122
Received 21 November 2001/ Returned for modification 22 January 2002/ Accepted 7 May 2002
|
|
|---|
|
|
|---|
Myc is a transcriptional factor that forms a heterodimer with Max through its helix-loop-helix-leucine zipper domain (15). The Myc/Max heterodimer binds to target genes at a consensus CACGTG motif and activates transcription at least in part by modifying the local chromatin through histone acetylation (4, 11, 26). Myc presumably controls cellular growth through the regulation of a set of target genes, although the identities of the sets of genes that control individual cellular phenotypes remain largely unknown (8). A large number of genes demonstrating a Myc-dependent pattern of expression have been identified recently through the use of differential screening and microarrays (3, 7, 16, 28, 35), but the direct participation of Myc in most gene regulation has not been verified. The most compelling evidence for direct Myc-dependent regulation is the ability to cross-link Myc to a specific chromosomal consensus binding site. Bona fide Myc target genes identified to date are involved in the control of cell proliferation (genes for cdk4, cyclin D2, Id2, Cul1, etc.) (5, 18, 23, 30) and in certain steps in the biosynthesis of nucleotides (CAD) and polyamines (ODC) (1, 27). The findings for CAD and ODC imply that in addition to controlling the cell cycle, Myc also regulates the growth of the cell. In support of this idea, the loss of myc gene function in Drosophila melanogaster results in decreased body sizes of adult flies, and overexpression of Myc results in an increased cell size without an increase in cell number (20). Furthermore, c-myc-null fibroblasts have reduced rates of protein synthesis (25), and overexpression of Myc stimulates expression of ribosomal proteins (3, 16). However, despite a growing number of Myc-responsive genes, the activities of Myc, especially the control of cell proliferation, have not been attributed in full to the transcriptional regulation of a particular gene or group of genes.
In the present paper, we report the isolation of a novel Myc target gene through functional screening of a myc-depleted cDNA library in c-myc-null rat fibroblasts. The gene encodes mitochondrial serine hydroxymethyltransferase (mSHMT), whose overexpression partially rescues the slow growth of c-myc-null fibroblasts. We demonstrate that the gene encoding cSHMT, the cytoplasmic isoform of mSHMT, is also a Myc-responsive gene, emphasizing the importance of the SHMT enzyme pathway in Myc-induced phenotypes. Reactions catalyzed by the mSHMT and cSHMT enzymes provide a major source of the one-carbon unit required for a variety of metabolic reactions in the cell. Our data from functional screening identify new Myc target genes involved in a central metabolic process in the cell.
|
|
|---|
Library preparation and CFSE selection. HO15.19 cells were transduced with pLXSH vector carrying mouse N-myc cDNA, which contains a unique SfiI site. Digestion with SfiI disrupts the N-myc coding region, rendering it functionally inactive. After the cells were infected and selected for hygromycin, total cellular RNA was isolated with TRIzol reagent (GIBCO/BRL) and poly(A) RNA was isolated with oligo(dT) cellulose (Ambion). cDNA was prepared with a SuperScript Choice System for cDNA Synthesis kit (GIBCO/BRL) and cloned into the modified pREBNA vector (32). The modified pREBNA vector contains bacterial ori sequences downstream of the polylinker and Lox sequences inserted into the NheI site in the 5' and 3' long terminal repeats. The library was digested extensively with SfiI, followed by transfection into packaging cells and subsequent infection into DK cells according to standard protocols. After infection, cells were stained with 10 µM carboxyfluorescein diacetate succinilmidyl ester (CFSE; Molecular Probes) in suspension in growth medium (3 x 106 cells/ml) for 5 min at 37°C, washed three times with 10 ml of ice-cold medium, and plated on 150-mm-diameter tissue culture dishes (106 cells/dish). CFSE is a vital fluorescent dye that irreversibly binds to cellular macromolecules. After 5 days, cells were collected and analyzed by flow cytometry, and a population of sorted cells (usually the 2 to 5% of cells with the lowest content of CFSE) was replated. After the cell population on the plates was expanded, cells were subjected to the second round of CFSE staining and sorting. To rescue retroviral vectors integrated into the cellular genome, we utilized a strategy proposed earlier (17). Briefly, 105 cells obtained after the second sort were infected with a retrovirus encoding the Cre protein, which binds to Lox sites in long terminal repeats of the integrated pREBNA vector and excises a circular double-stranded DNA containing one chimeric LTR, a cDNA insert, and bacterial ori sequences. At 36 to 48 h postinfection, cells were lysed in buffer P1 from a QIAGEN plasmid minikit, followed by treatment with solutions P2 and P3, according to the kit's instructions. Plasmid DNA was cloned through standard transformation of competent Escherichia coli bacteria.
Chromatin immunoprecipitation (ChIP). HEK 293 or Raji cells were cross-linked by adding formaldehyde (final concentration, 1%; Fisher Scientific) directly to the cells on a rocking tissue culture dish for 10 min at room temperature. Cross-linking was terminated by the addition of glycine to a final concentration of 125 mM. Fixed cells were washed with ice-cold phospate-buffered saline containing 0.5 mM phenylmethylsulfonyl fluoride (PMSF) and then scraped in swelling buffer {5 mM PIPES [piperazine-N,N'-bis(2-ethanesulfonic acid), pH 8.0], 85 mM KCl, 0.5% NP-40, 0.5 mM PMSF, and 100 ng (each) of leupeptin and aprotinin per ml}. Cells were incubated on ice for 20 min, followed by Dounce homogenization. Nuclei were harvested by centrifugation (4,500 x g) and then resuspended in sonication buffer (0.1% sodium dodecyl sulfate, F buffer [39a], 0.5 mM PMSF, 100 ng [each] of leupeptin and aprotinin per ml) and sonicated on ice to obtain 1,000- to 2,000-bp-long DNA fragments. After sonication, lysates were cleared by microcentrifugation at 14,000 rpm. Lysates were normalized according to measurements of their optical densities at 260 nanometers. Each lysate was diluted six times with dilution buffer (F buffer, 0.5 mM PMSF, 100 ng [each] of leupeptin and aprotinin per ml) and normalized by dilution in IP buffer (0.015% sodium dodecyl sulfate, F buffer, 0.5 mM PMSF, and 100 ng [each] of leupeptin and aprotinin per ml). The normalized chromatin lysates were precleared overnight with preblocked protein A/G beads. Protein A or G beads were preblocked by incubation for 3 h at 4°C in IP buffer containing 1 µg of salmon sperm DNA per ml and 1 µg of bovine serum albumin per ml. Precleared lysates were incubated at 4°C overnight with 1.5 µg of anti-Myc (N262; Santa Cruz) or 5 µl of anti-Gal4 (sc-429; Santa Cruz). Beads were washed and eluted, followed by reversal of the cross-linking (22) and DNA isolation performed with a QIAGEN PCR purification kit. Eluted material was subjected to quantitative PCR amplification. PCR was performed with the following sets of primers: human mSHMT promoter-specific primers SC-25 (CGAGTTGCGATGCT-GTACTTCTCT) and SC-26 (GCTCGGTTGCATCATCTGCA), human cSHMT promoter-specific primers cprSHT5 (AGCGACAGGCTTAAGTGAGG) and cprSHT3 (GTGCCACCAGTCCCAGAC), human TERT-specific primers SC-9 (AGTGGATTCGCGGGCACAGA) and SC-10 (AGCACCTCGCGGTAGTGGCT), human chromosome 22-specific primers Chr22a (TTACAGGTAAGCACCTCCATGACC) and Chr22b (GCAAAAGCTACCATTTAGGAACCC), rat mSHMT-specific primers RmSHMTs (CTGGATGACCAGTGGAAAGG) and RmSHMT (GACCCTTGCGTGATGAAAGT), rat nucleolin-specific primers NUCLa (CTGGGAGGGCGATGTAGAGT) and NUCLb (GGAAGGGGGTTATCTCGAAG), and rat glucokinase-specific primers GLUa (TGCCCGATTTTCATCTTCTT) and GLUb (CCAAGGACTTCCGCACTAAC).
To normalize samples by the amount of nonspecific DNA, we amplified regions in the promoters of the rat PCNA gene (PCNa [CGAAGCACCCAGGTAAGTGT] and PCNb [ATCGTATCCGTGGTTTGAGC]) and in the third intron of the human ß-globin gene (SC-46 [ATCTTCC-TCCCACAGCTCCT] and SC-47 [TTTGCAGCCTCACCTTCTTT]). One of the primers in each pair was end labeled with [
-32P]ATP. Amplification was performed in a model T3 thermocycler (Biometra) for 31 cycles at 94°C for 45 s, 60°C for 45 s, and 72°C for 60 s, followed by a final extension step at 72°C for 5 min. The optimal number of cycles for exponential amplification was determined by kinetic analysis. PCR products were resolved on a 4 or 6% polyacrylamide gel. PCR products were quantitated and normalized with the Molecular Dynamics PhoshphorImaging system.
|
|
|---|
![]() View larger version (22K): [in a new window] |
FIG. 1. Outline of the experimental strategy. The dotted lines indicate the CFSE profiles of initial populations before the first cell sorting. The shaded area below the peak designates cells taken for the next step of analysis. Note the gradual decrease in the intensity of CFSE staining of cells after each sorting. See details in the text and Materials and Methods.
|
![]() View larger version (24K): [in a new window] |
FIG. 2. Overexpression of mSHMT enhances proliferation of c-myc-null cells. (A) FACS profiles of DK cells (thin line), c-myc-null cells (HO15.19) infected with a c-myc-expressing vector (dotted line), and DK cells infected with a cDNA expression library (bold line) after two rounds of sorting. (B) FACS profiles of DK cells infected with either empty vector (thin line) or an mSHMT-expressing vector (bold line) after one round of sorting. c-myc-null cells (HO15.19) infected with a c-myc expression vector before the sorting are shown with a dotted line. (C) CFSE profile of c-myc-null cells (HO15.19) infected as described for panel B and selected for resistance to hygromycin (see Materials and Methods). (D) Doubling times of DK, c-myc-null, and Rat-1 cells expressing the constructs indicated below each bar.
|
We were interested in whether overexpression of mSHMT rescues the slow growth of the original c-myc-null cells (HO15.19). To this end, we transduced an mSHMT-expressing vector or an empty vector into c-myc-null cells or DK cells, followed by selection on hygromycin for 7 days. The growth rate of the resulting cell populations was determined by both CFSE staining and the direct determination of the cell doubling time (Fig. 2). Overexpression of mSHMT partially rescued the slow-growth phenotype of HO15.19 and DK cells, as visualized by the peak of staining with CFSE (Fig. 2C). The doubling time of the c-myc-null cells decreased from 47.1 ± 1.9 h to 39.0 ± 1.4 h for myc-null mSHMT-expressing cells (n = 4, P = 0.0173) and from 40.9 ± 1.8 h for DK cells to 35.5 ± 1.3 h for DK mSHMT-expressing cells (n = 3, P = 0.0333). It is noteworthy that overexpression of mSHMT in the parental Rat-1 cells did not enhance their growth rate (Fig. 2D).
mSHMT and cSHMT genes are direct targets of Myc. Our next goal was to determine if mSHMT is indeed a Myc target gene. We used Northern blot analysis of RNAs isolated from c-myc-null cells and parental Rat-1 cells (which possess wild-type c-myc genes). As shown in Fig. 3A, mSHMT expression is strongly induced by serum in Rat-1 cells whereas the induction is severely attenuated in c-myc-null cells. We also compared the profiles of mSHMT expression in logarithmically growing Rat-1 cells, c-myc-null cells, and c-myc-null cells reconstituted with a c-myc cDNA. The level of mSHMT RNA was enhanced in Myc-reconstituted c-myc-null cells compared to that of the original c-myc-null cells transduced with empty vector, implying that mSHMT is a downstream target of c-Myc. We also noted a second, slower-migrating mSHMT RNA in serum-stimulated myc-null cells that is under investigation. We note that mSHMT is still expressed basally in log-phase myc-null cells and is inducible to some extent by serum, indicating that other factors also regulate mSHMT expression.
![]() View larger version (52K): [in a new window] |
FIG. 3. Genes for mSHMT and cSHMT are Myc-responsive genes. (A) RNA isolated from serum-stimulated or logarithmically growing c-myc-null cells (lanes marked -), parental Rat-1 cells (lanes marked +), or c-myc-null cells expressing a c-myc cDNA (lane m) was probed in a Northern blot with an mSHMT-specific probe. Ethidium bromide-stained 28 and 18S rRNAs are shown in each lane as a loading control. The numbers above the blots indicate times after serum induction. (B) c-myc-null cells expressing c-Myc-ER were passaged several times under subconfluent conditions (<50% confluence) to obtain cells in an exponential phase of growth. 4-OH was added directly to the medium at a final concentration of 200 nM. RNA was collected following the addition of 4-OH at the time intervals shown above the blots. RNA was also collected from untreated cells at the same time intervals. RNA was probed sequentially by Northern blotting with mSHMT and GAPDH probes. A number below a blot indicates the fold induction of the mSHMT-specific message normalized to the amount of GAPDH in each lane at each time point. (C) RNA isolated from logarithmically growing c-myc-null cells (lane marked -), parental Rat-1 cells (lane marked +), or c-myc-null cells expressing a c-myc cDNA (lane m) was sequentially hybridized by Northern blotting with probes specific for mSHMT, cSHMT, and GAPDH. (D) RNA was isolated from logarithmically growing colon carcinoma cells (HCT116 and Colo320) or neuroblastoma cells (SK-NSH, SK-NAS, CHP-134, IMR32) and sequentially hybridized by Northern blotting with probes specific to the mSHMT, cSHMT, c-myc, or N-myc gene. Ethidium bromide-stained 28 and 18S rRNAs are shown in each lane as a loading control.
|
As mentioned above, there are two SHMTs (mitochondrial and cytoplasmic) that are major suppliers of one-carbon units for cellular biosynthesis. Since we demonstrated that mSHMT is a Myc target gene, we were interested in determining whether the expression of cSHMT is also Myc regulated. To this end, we hybridized RNA obtained from Rat-1 cells, c-myc-null cells, and Myc-reconstituted c-myc-null cells by employing Northern blotting with a probe specific to mouse cSHMT. As shown in Fig. 3C, the level of cSHMT mRNA is significantly higher in cycling Rat-1- or Myc-reconstituted c-myc-null cells than in cycling c-myc-null cells infected with empty vector. Expression of cSHMT was also induced in Myc-ER cells by treatment with 4-OH, suggesting that the cSHMT gene is also a Myc target gene (data not shown).
Since c-myc and N-myc genes are often amplified in tumors, we were interested in learning whether the level of mSHMT or cSHMT mRNA is also elevated in tumor cells with large amounts of the Myc protein. SHMT expression was analyzed in colon carcinoma cell lines with amplified (Colo320) or normal (HCT116) c-myc genes and in neuroblastoma lines with amplified (CHP134, IMR32) or normal (SK-NSH, SK-NAS) N-myc genes. As shown in Fig. 3D, expression of both SHMT genes was higher in tumor cell lines with amplified myc genes than in cells with lower Myc levels.
In vivo cross-linking of c-Myc to the SHMT promoters. Sequence analysis of cytosolic SHMT and mSHMT genes in different species revealed that their promoters contained one or two Myc consensus binding sites (Fig. 4A). We wanted to determine if Myc actually binds to these sites in vivo. To this end, we obtained cross-linked chromatin from either myc-null cells and Myc-reconstituted null cells (Fig. 4B) or from human HEK293 cells and Raji cells, which have high levels of the c-Myc protein (Fig. 4C). The chromatin was immunoprecipitated with either anti-c-Myc antibodies or with control anti-Gal4 antibodies (ChIP). After reversion of the cross-linking, DNA was purified and subjected to PCR with primers flanking the region of the SHMT promoters encompassing the potential Myc binding sites (Fig. 4A). As a control for DNA quantitation and nonspecific background, we performed PCR on the same DNA samples with primers to chromosomal sites that are not expected to bind to Myc protein in vivo. In myc-null cells, there was no enrichment in the anti-Myc ChIP experiment for the Myc target gene nucleolin or for mSHMT, nor was there any enrichment for the nontarget gene products glucokinase (which contains a Myc/Max consensus site) and PCNA. In contrast, reconstitution of Myc expression in myc-null cells led to four- to fivefold enrichment of both mSHMT and nucleolin genomic DNA fragments in the anti-Myc ChIP but not in the control anti-Gal4 ChIP samples (Fig. 4B). No binding of Myc to glucokinase or PCNA was observed. In Raji and HEK293 cells, there was a substantial enrichment for mSHMT and cSHMT genomic DNA in the anti-Myc ChIP (3.5- to 20-fold) that paralleled the enrichment for the Myc target gene TERT (2.4- to 11-fold) (Fig. 4C). There was no enrichment of a nonfunctional Myc consensus sequence on chromosome 22 or of the nontarget ß-globin gene. Equivalent background signals were obtained for all samples with the control ß-globin primers. It is noteworthy that the highest signal-to-noise ratio (20-fold) was observed for the mSHMT gene in Raji anti-Myc ChIP samples, which have the highest Myc protein levels. Thus, ChIP demonstrates the direct binding of c-Myc to both the mSHMT and cSHMT promoters, consistent with the above data on Myc-dependent expression of these genes.
![]() View larger version (35K): [in a new window] |
FIG. 4. c-Myc binds to the promoters of mSHMT and cSHMT genes in vivo. (A) Schematic presentation of human, mouse, and rat mSHMT and cSHMT promoters. Open boxes represent exons. Myc binding sites and ATG codons are shown. Arrows indicate the positions and direction of primers used in PCR. (B and C) HO15.19 cells infected with empty vector (+vector lanes), HO15.19 cells infected with c-myc-expression vector (+myc lanes), HEK 293 cells, or Raji cells were cross-linked and lysed, and chromatin was immunoprecipitated with c-Myc-specific (M lanes) or Gal4-specific (G lanes) antibodies, followed by the reversal of the cross-linking and DNA isolation. Isolated DNA was used in PCR with radiolabeled oligonucleotides flanking Myc binding sites in the promoters of the genes indicated to the right of the blots. For negative controls, two types of PCR were performed. The first one was carried out with oligonucleotides flanking CACGTG sites that do not interact with c-Myc in the promoter of the rat glucokinase gene (GLU) (11) (B) or somewhere on human chromosome 22 (Chr. 22) (4) (C). Another PCR was performed with oligonucleotides flanking a DNA region containing no CACGTG sites in the rat PCNA gene (B) or in the third intron of a silent human ß-globin gene (C). Quantitation of the PCR products was performed with the Molecular Dynamics IhoshphorImaging system. A number below the a blot indicates the fold difference in the signal intensity, determined by dividing a given PCR signal by a corresponding PCNA-specific (B) or ß-globin-specific (C) signal and by the ratio of these signals in the corresponding Gal4 lane.
|
|
|
|---|
SHMT catalyzes the conversion of serine and THF to glycine and methylene-THF (reviewed in reference 39). This reaction generates most of the one-carbon units for thymidylate, purine, and methionine synthesis. Two separate genes encode the mitochondrial (mSHMT) and cytoplasmic (cSHMT) forms of the enzyme (13, 14, 40). It remains unclear why a cell has both enzymes, since the mitochondrial form is the main source of one-carbon units for both mitochondrial and cytoplasmic folate metabolism and nucleoside biosynthesis (12). Interestingly, culturing of myc-null cells or myc-null cells overexpressing cyclin D1/cdk4 in high concentrations of nucleotides, formate, or methionine does not provide any growth enhancement (data not shown), indicating that it is not possible to complement this biochemical pathway by simple substrate replacement. This suggests that localized SHMT activity produces one-carbon-unit-substituted folate cofactors that may have a unique influence on cell growth and/or proliferation. In Saccharomyces cerevisiae, the two SHMT enzymes are not essential due to redundant biosynthetic pathways. However, strains defective in both enzymes exhibit severe growth defects under specific culture conditions (21). Furthermore, CHO cells lacking mSHMT are glycine auxotrophs (33). We speculate that mSHMT activity may become rate limiting for growth in c-myc-null cells in part because of other metabolic pathways that are simultaneously down-regulated in response to the Myc deficiency.
The full extent of the metabolic pathways that are under Myc control will require further study. The SHMT genes join those for CAD, ODC, LDH-A, IRP2, and others as direct Myc targets involved in basic cellular metabolism (1, 27, 36, 43). Both the LDH-A and IRP2 genes are components of general cellular growth pathways, but they have not been shown to contribute directly to the growth rate, as we show here for mSHMT. The importance of Myc in the control of cellular growth is highlighted by studies of Drosophila, where Myc gain of function or loss of function controls cell size without any concomitant change in cell number (20). These observations link Myc expression to cellular growth and only indirectly to the cell cycle. Overexpression of Myc in B cells also leads to an increase in cell size (19, 34a). In contrast to these influences on cellular growth, several mammalian genes with direct roles in the control of the cell cycle have been shown to be Myc targets, including the genes for cyclin D2, cdk4, and cul1. cul1 has been reported to rescue the growth defect in primary myc-null fibroblasts (30), and cdk4 has a modest growth-enhancing effect in immortalized c-myc-null fibroblasts (18). Cyclin D2 is reported to be required for Myc-dependent cell proliferation (5), but ectopic expression of cyclin D2 does not stimulate the growth of c-myc-null cells (2). Finally, reduced expression of c-myc led to smaller embryos with fewer cells in most major organs, rather than smaller cells (42). Thus, it appears that in mammals, Myc controls both basic cellular growth pathways and progression through the cell cycle. The identification of mSHMT as a Myc target for cellular growth provides an important insight into the ability of Myc to regulate cellular metabolism. A screen for cDNAs that synergize with mSHMT to further enhance the growth rate of Myc-deficient cells may reveal additional rate-limiting components of the Myc pathway.
This work was supported by grants from the NIH to M.D.C. and J.M.S.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»